[OFER-TRABEC] NAC: POSTDOC POSITION - MOLECULAR BIOLOGY

***********************************************************************
(c)OFER-TRABEC es un servicio ofrecido por el Centro de Comunicaciones RedIRIS
(Permitida la reproducción siempre que se cite la fuente de este Servicio).
***********************************************************************
Becas, ayudas y subvenciones
http://www.060.es/te_ayudamos_a/ayudas_becas_y_subvenciones/common/becas.pdf
***********************************************************************
Se agradece la colaboración del:
Centro de Información Administrativa de Presidencia del Gobierno
*************************************************************************
RedIRIS ofrece de forma gratuita la creación Listas de distribución
de interés academico y científico http://www.rediris.es/list/crealist.html
*************************************************************************

---Procedencia:
Institución:Vall d'Hebron Research Institute - BARCELONA
Contacto correo-e:darango@ir.vhebron.net
---
POSTDOCTORAL POSITION IN MOLECULAR ONCOLOGY
Barcelona, Spain

We are currently looking for a highly motivated candidate to join the Group of Molecular Oncology at Vall d'Hebron Hospital, Barcelona, Spain (see http://nanomedicine.cibbim.net/ and www.ir.vhebron.net). The successful candidate will join a translational research line aimed at the functional characterization of new genes involved in tumor progression. The candidate will be expected to join the group in January 2011.

THE CANDIDATE SHOULD:
- Have a doctoral degree in molecular biology or related fields.
- At least one year of postdoctoral experience is preferred.
- Good publication record in the field of Molecular Oncology.

WE OFFER:
- Postdoctoral position for one year that could be further extended.
- 25.000 Euros per year.
- Stimulating research environment.

CONTACT:
Please, contact Dr. Diego Arango before 30-November-2010: darango@ir.vhebron.net.

----------------
Información complementaria de la oferta:
SELECTED PUBLICATIONS

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D. Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment. Clinical Cancer Research. 2010 Apr 15;16(8):2375-82.

Dopeso H, Mateo S, Mazzolini R, Rodrigues P, Lagares-Tena L, Ceron J, Romero J, Esteves M, Landolfi S, Hernández-Losa J, Castaño J, Wilson AJ, Ramon y Cajal S, Mariadason JM, Schwartz Jr S, Arango D.. EPHB4 has tumor suppressor activities in intestinal tumorigenesis. Cancer Research 2009 Sep 15;69(18):7430-8

Romero-Giménez J, Dopeso H, Guerra A, Blanco I, Schwartz Jr S, Arango D. Germline hypermethylation of the APC promoter is not a common cause of FAP/AFAP. International Journal of Cancer 2008 Mar 15;122(6):1422-5

Davalos v, Dopeso H, Velho S, Monteiro Ferreira A, Cirnes L, Díaz-Chico N, Bilbao C, Ramírez R, Rodríguez G, Falcón O, León L, Niessen R, Keller G, Dallenbach-Hellweg G, Espín E, Armengol M, Perucho M, Imai K, Yamamoto H, Gebert JF, Díaz-Chico JC, Hofstra RM, Woerner SM, Seruca R, Schwartz Jr. S, Arango D. High EPHB2 mutation rate in gastric but not endometrial tumors with microsatellite instability. Oncogene, 2007;26(2):308-11

Davalos V, Dopeso H, Castaño J, Wilson AJ, Vilardell F, Romero-Gimenez J, Espín E, Armengol M, Capella G, Mariadason JM, Aaltonen LA, Schwartz Jr. S, Arango D. EPHB4 and survival of colorectal cancer patients. Cancer Research, 2006; 66(18):8943-8948

Ropero S, Fraga MF, Ballestar E, Hamelin R, Yamamoto H, Arango D, Aaltonen LA, Schwartz S Jr, Esteller M. A truncating mutation of HDAC2 in human cancers confer resistance to histone deacetylase inhibition. Nature Genetics, 2006;38(5):566-9

*************************************************************************
Para darse de baja OFER-TRABEC pinche y envíe:
mailto:OFER-TRABEC-signoff-request@listserv.rediris.es
*************************************************************************